GSK3 is prominent for its role in apoptosis signaling and has been shown to be involved in Parkinson's disease (PD) pathogenesis. The overall effects of GSK3 activity on cell fate are wellestablished, but the effects of mitochondrial GSK3 activity on mitochondrial function and cell fate are unknown. Here we selectively expressed constitutively active GSK3 within the mitochondria and found that this enhanced the apoptosis signaling activated by the PD-mimetic NADH:ubiquinone oxidoreductase (complex I) inhibitors 1-methyl-4-phenylpyridinium ion (MPP + ) and rotenone. Additionally, expression of GSK3 in the mitochondria itself caused a significant decrease in complex I activity and ATP production. Increased mitochondrial GSK3 activity also increased reactive oxygen species production and perturbed the mitochondrial morphology. Conversely, chemical inhibitors of GSK3 inhibited MPP + -and rotenone-induced apoptosis, and attenuated the mitochondrial GSK3 -mediated impairment in complex I. These results indicate that unregulated mitochondrial GSK3 activity can mimic some of the mitochondrial insufficiencies found in PD pathology.
INTRODUCTION
Glycogen synthase kinase-3ß (GSK3 ) has emerged as a major therapeutic target due to its involvement in several neurodegenerative diseases, including Parkinson's disease (King et al., 2001; Chen et al., 2004; Jope and Johnson, 2004; Avraham et al., 2005; Chung et al., 2007; Wang et al., 2007; Yuan et al., 2008) . GSK3 was originally discovered as a regulator of glycogen synthesis (Parker et al., 1982) . However, GSK3 has also been shown to affect numerous cellular mechanisms including cell fate. GSK3 is typically constitutively active but phosphorylation at Ser-9 of GSK3 markedly attenuates its activity. In addition, GSK3 can be regulated by protein complex formation (Jope and Johnson, 2004) , which is independent of phosphorylation at Ser-9. GSK3 was initially thought to be localized in the cytosol (Hemmings et al., 1981) . In fact, the largest pool of GSK3 does exist in the cytosol, but lesser amounts can be found in the nucleus (Diehl et al., 1998; Xavier et al., 2000; Bijur and Jope, 2001 ) and in the mitochondria (Bijur and Jope, 2003a,b; Hoshi et al., 2003) . The existence of GSK3 in mitochondria suggests that it has access to substrates resident in this organelle, which could include proteins of the intrinsic apoptosis pathway sequestered in healthy mitochondria, as well as mitochondrial metabolic proteins. Numerous studies have listed the ramifications of unregulated GSK3 on cell fate, but to date the effects of unregulated mitochondrial GSK3 on the mitochondria and apoptosis signaling are largely unknown.
GSK3 is well known to play a role in apoptosis signaling. Unregulated GSK3 activity can activate apoptosis signaling on its own (Pap and Cooper, 1998) , or enhance apoptosis by toxic stimuli that trigger mitochondrial-dependent apoptosis signaling. For example, GSK3 facilitates cell death induced by stressors such as heat shock (Bijur et al., 2000) , osmotic stress (Rao et al., 2004) , the generic apoptosis inducer staurosporine (Bijur et al., 2000) , growth factor withdrawal (Hetman et al., 2000) , mitochondrial toxins such as rotenone (King et al., 2001) , endoplasmic reticulum toxins such as thapsigargin , and genotoxic agents such as camptothecin (Watcharasit et al., 2002) . Interestingly, both thapsigargin and camptothecin have been shown to increase GSK3 activity within the mitochondria Watcharasit et al., 2002) . Conversely, inhibitors of GSK3 have been found to be neuroprotective. The classical GSK3 inhibitor lithium has been shown to provide protection against a host of physical and chemical stressors. Thus, an overall increase in GSK3 activity appears to enhance the lethality of various toxic stimuli by decreasing the ability of cells to mount a vigorous survival response.
Since many studies thus far have focused on outcomes related to overall increases in GSK3 activity, the goal of this study was to determine the ramifications of unregulated GSK3 activity within the confines of the mitochondria of SH-SY5Y neuroblastoma cells and to measure cellular responses to an increase in mitochondrial GSK3 activity. This report shows that increased mitochondrial GSK3 activity robustly inhibits NADH:ubiquinone oxidoreductase (complex I) activity, causes oxidative stress, potentiates caspase-3 activation by the Parkinson's disease-mimetic toxins 1-methyl-4-phenylpyridinium (MPP + ) and rotenone, and causes gross alterations in mitochondrial morphology.
METHODS

Materials
GSK3 inhibitor II was purchased from EMD Chemicals (Gibbstown, NJ) and all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Plasmid Construction and Lentivirus Preparation
The constitutively active GSK3 (in which the Ser9 of GSK3 has been mutated to an Ala, S9A) fused to a mitochondrial localization sequence (MSVLTPLLLRGLTGSARRLPVPRAKIHSL) from subunit VIII of cytochrome oxidase pBIG2r construct (mS9AGSK3 ) was a generous gift from Dr. Richard S. Jope (University of Alabama at Birmingham). The mitochondrial-targeted green fluorescent protein (pCMVMitoGFP or mGFP), which is used as a control in these studies, was purchased from Invitrogen (Carlsbad, CA). The pENTR Directional TOPO Cloning Kit (catalog number K2400-20) and the ViraPower Lentivirus Expression System (catalog numbers K4965-00 and K4967-00; Invitrogen) were used according to the manufacturer's instructions to package the plasmid constructs into lentivirus particles.
Production of Stable-inducible Cell Lines and Treatments
Human neuroblastoma SH-SY5Y cells were used to make stable cell lines that conditionally express mS9AGSK3 and mGFP in the presence of doxycycline, an analog of tetracycline. Briefly, wildtype SH-SY5Y cells were initially transduced with the tetracycline (Tet) repressor lentivirus (Lenti6/ TR) construct using the Magnetofection-ViroMag R/L transduction kit (OZ Biosciences, Marseille, France) to enhance the efficiency of transduction for low viral titers. The cells were selected with 2 g/ml blasticidin 24 h post-transduction and were allowed to grow for several days to allow time for the Tet repressor expression levels to increase. Subsequently, the Tet repressor stable cell lines were seeded (2.0 x 10 5 cells/plate) in 35 mm dishes and were transduced with the mS9AGSK3 (9.85 × 10 3 ) or mGFP (4.6 × 10 3 ) lentivirus constructs, using the Magnetofection-ViroMag R/L transduction kit, to establish stable-inducible cell lines for each of the constructs. The cell lines were grown in DMEM/F12 media (Cellgro, Herndon, VA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine, and 100 U/ml penicillin/100 g/ml streptomycin. Cells were kept under selection with 50 g/ml Zeocin and 2 g/ml blasticidin until they were cultured for experimentation.
GSK3 Kinase Assay
Cells were lysed in immunoprecipitation (IP) lysis buffer (20 mM Tris, pH 7.5, 0.2% Nonidet P-40, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1 mM sodium orthovanadate, 100 M phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 10 g/ml aprotinin, 5 g/ml pepstatin, 1 nM okadaic acid, and 100 mM sodium fluoride). The lysates were sonicated in microcentrifuge tubes for 10s on ice and centrifuged at 20,800g for 15 min. After the protein concentration was determined by using the bicinchoninic acid method (Pierce, Rockford, IL), 100 g of protein (1 g/ l) was precleared with 60 l of protein G-Sepharose beads for 3 h at 4°C then incubated with 2 g of monoclonal GSK3 antibody (Pharmingen/Transduction Laboratories) for 3h at 4°C with gentle agitation. The immobilized immune complexes were washed three times with IP lysis buffer and three times with kinase assay buffer (20 mM Tris, pH 7.5, 5 mM MgCl 2 , 1 mM dithiothreitol). Kinase activity was assayed in a total volume of 30 l of kinase buffer containing 20 mM Tris, pH 7.5, 5 mM MgCl 2 , 1 mM dithiothreitol, 250 M ATP 1.4 Ci of [ -32 P]ATP, and 100 M phosphorglycogen synthase peptide-2 (YRRAAVPPSPSLSRHSSPHQSEDEEE) (Upstate Biotechnology, Inc., Lake Placid, NY). Glycogen synthase (Ala21) peptide-2 was used as a negative control. The samples were incubated at 30°C for 30 min, the reaction tubes were centrifuged for 1 min, and triplicate 9-l aliquots of reaction supernatants were spotted onto 1 cm × 2 cm P81 filter paper. The filter papers were washed 4 times in 0.5% phosphoric acid for a total time of 1h, rinsed in 95% ethanol, air-dried, and counted in a liquid scintillation counter. The efficiency of GSK3 immunoprecipitation was determined by immunoblotting for GSK3 .
Immunofluorescence
Cells (mGFP and mS9AGSK3 ) were cultured on poly-D-lysine-coated glass cover slips and subjected to treatments as indicated. The cells were treated with 1 nM MitoTracker (red-CMX-ROS, Invitrogen) for 1 h at 37°C, washed twice with warm phosphate buffered saline (PBS), then fixed and permeabilized with 2% paraformaldehyde for 20 min at 37°C and 0.1% triton-X 100 at room temperature for 5 min, respectively. The cover slips (mS9AGSK3 cells) were washed twice with PBS and incubated overnight at 4°C with mouse monoclonal anti-GSK-3ß antibody (1:250) diluted in PBS containing 5% bovine serum albumin (BSA). The cover slips were washed with PBS and incubated with anti-mouse Alexafluor green secondary antibody (1:4,000) in PBS containing 5% BSA for 1 h at room temperature. The cover slips were washed once with PBS, twice with deionized water, and were incubated with 0.2 g/ml Hoechst 33342 at room temperature for 1 h. The cover slips were washed with deionized water, mounted onto glass slides using Gel/Mount (Biomeda Corp., Foster City, CA), and examined by a fluorescent microscope (MicroBright Field, Inc.) set at 40x and 100× magnification.
Immunoblotting
Cells were washed twice with PBS and lysed in IP lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1 mM sodium orthovanadate, 100 M phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 10 g/ml aprotinin, 5 g/ml pepstatin, 50 mM NaF, 1 nM okadaic acid, and 0.5% NP-40). The lysates were centrifuged at 20,817g for 10 min at 4°C and supernatants were collected. To obtain crude mitochondrial extracts, cells were washed with PBS, harvested in cavitation buffer (5 mM HEPES, pH 7.4, 3 mM CaCl 2 , 1 mM EGTA, and 250 mM sucrose), and lysed by nitrogen cavita-tion (Bijur and Jope, 2003a) . Lysed cells were centrifuged at 500g for 5 min, and the supernatant was centrifuged at 16,000g for 10 min. The membrane pellet was washed three times with cavitation buffer and lysed in IP lysis buffer. Protein concentrations were determined by using the bicinchoninic acid method. Cell lysates were mixed with Laemmli sample buffer (2% SDS) and placed in a boiling water for 5 min. Proteins (10 g) were resolved in 7.5% SDS-polyacrylamide gels, and transferred to nitrocellulose. Blots were probed with antibodies to total GSK3 (BD Transduction Laboratories, Lexington, KY), PARP (Cell Signaling Technologies, Beverly, MA), and V5-tag (Invitrogen, Carlsbad, CA). Immunoblots were developed using horseradish peroxidaseconjugated goat anti-mouse or goat anti-rabbit IgG (Bio-Rad Laboraories, Hercules, CA), followed by detection with enhanced chemiluminescence. Immunoblots were quantitated by scanning densitometry using UN-SCAN-IT image digitizing software (Silk Scientific Inc., Orem, Utah).
Transmission Electron Microscopy
Cells from each sample were collected and fixed with Karnovsky's fixative (2% paraformaldehyde/2.55 glutaraldehyde in 0.1 M sodium cacodylate buffer). Subsequently, the samples were rinsed several times with Karnovsky's buffer followed by post fixation with 1% osmium tetroxide for 1 h. The samples were rinsed with PBS for 1 h and were dehydrated through a series of graded ethyl alcohols from 50% to 100%. After dehydration the samples were infiltrated with two changes of 100% propylene oxide for 10 minutes each and a 50:50 mixture of propylene oxide and the embedding resin (Embed 812, Electron Microscopy Sciences, Fort Washington, PA) for 12-18 h. The samples were then transferred to fresh 100% embedding media twice for at least 1 h. The tissue was then embedded in a fresh change of 100% embedding media. Following 12-18 h in the oven at 60°C for polymerization, the blocks were then ready to section. The resin blocks were sectioned at 1-2 microns with a diamond histo knife using an ultramicrotome and stained with Toluidine Blue. These sections were used as a reference to trim blocks for thin sectioning. The appropriate blocks were then thin sectioned using a diamond knife (Diatome, Electron Microscopy Sciences) at 70-100 nm and sections were placed on either copper or nickel mesh grids. The sections were stained with uranyl acetate and lead citrate for contrast. The grids were then viewed on a FEI Tecnai Twin 120kv transmission electron microscope (FEI, Hillsboro, OR). Digital images were taken with an AMT CCD camera, and stored on a memory storage device. Images were analyzed and quantitated by Image J. Briefly, 48 to 62 mitochondria per grid were randomly circumscribed and the area was quantitated for each mitochondrion.
Complex I Activity Assay
Complex I activity was determined by measuring the rate of NADH oxidation at 340 nm using ubiquinone-2 as the electron acceptor. The rate sensitivity to rotenone (10 M) was taken to be complex I activity (Milakovic et al., 2005) . Crude mitochondrial extracts were used to measure complex I activity. Briefly, cells were washed with phosphate buffered saline, harvested in cavitation buffer (5 mM HEPES, PH 7.4, 3 mM CaCl 2 , 1 mM EGTA, and 250 mM sucrose), and lysed by nitrogen cavitation. Lysed cells were centrifuged at 700g for 5 min, and the supernatant was centrifuged at 16,000g for 10 min. The membrane pellet was washed three times with cavitation buffer and freeze-thawed three times (at -80°C) in cavitation buffer. Then the pellet was centrifuged at 16,000g for 5 min and was resuspended in 1 ml ddH 2 O. The pellet suspension was centrifuged at 16,000g for 5 min and resuspended in cavitation buffer. The pellet suspension was sonicated on ice three times at 10 second intervals. Protein concentration was determined by the bicinchoninic method and standardized (50 g) for the complex I assay.
ATP Production Assay
Mitochondria were isolated in cavitation buffer (5 mM HEPES pH 7.4, 3 mM MgCl 2 , 1 mM EGTA, 250 mM Sucrose) using nitrogen cavitation and centrifugation. Protein concentrations were determined prior to the assay using the bicinchoninic acid assay (Pierce). Mitochondrial protein (250 g) was used for each reaction, and the mitochondria were spun down, re-suspended in cavitation buffer, and were pelleted on ice until ready for use. For the ATP production assay, pellets were re-suspended in 190 l respiration buffer (20 mM HEPES-KOH pH 7.4, 80 mM KOAc, 5 mM MgOAc 2 , 250 mM sucrose, 1 mM pyruvate, 1 mM malate, or 5 mM succinate. Buffer B (0.5 M Tris-Acetate pH 7.75, 0.8 mM D-Luciferin, 20 g/ml luciferase) (10 l) was immediately added to the reaction, and sample luminescence was read in standard mode on a Turner 20/20 luminometer for 4 seconds with no delay. ADP was added to the sample at a final concentration of 0.1 mM, and the luminescence was read every 4 seconds for 160-180 seconds.
ROS Measurement
To measure intracellular production of ROS, cells were placed in Kreb's buffer (30 mM HEPES pH 7.4, 122 mM, 4.9 mM KCl, 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 1.3 mM CaCl 2 , 3.6 mM NaHCO 3 , and 11 mM glucose) and treated with 100 M 2,7-dichlorofluorescein diacetate (Molecular Probes, Eugene, OR) for 30 min at 37°C. Cells were washed twice with Kreb's buffer and sonicated in a buffer containing 50 mM KH 2 PO 4 , 0.1 mM EDTA, and 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane-sulfonate (pH 7.0). The mixture was centrifuged at 2000g for 10 min at 4°C. The supernatant was used to determine intracellular oxidant production by monitoring its florescence on a Bio-Tek Synergy fluorescence spectrophotometer at 485 nm excitation and 528 nm emission.
RESULTS
Overexpression of GSK3 in the Mitochondria
Previously it was shown that global overexpression of GSK3 in SH-SY5Y cells facilitates apoptosis by a variety of toxic stimuli. The goal was to examine how selectively increasing GSK3 activity in the mitochondria would affect apoptosis signaling. GSK3 expression was increased specifically within the confines of the mitochondria of SH-SY5Y cells. Stable cell lines were produced by lentivirusmediated gene transduction of a tetracycline (doxycycline)-inducible, constitutively active mutant of GSK3 , in which the regulatory Ser9 site was mutated to an Ala. A mitochondrial targeting sequence from subunit VIII of cytochrome oxidase, a mitochondrial inner membrane protein (Rizzuto et al., 1992) , was added at the N-terminus of the protein (mS9AGSK3 ). The initial goal was to test if the mitochondrial targeting sequence would direct the expressed proteins specifically to the mitochondria. Green fluorescent protein fused to the mitochondrial targeting sequence (mGFP) and mS9AGSK3 were transduced into cells by lentivirus (FIG. 1A) . Cells stably expressing mGFP and mS9AGSK3 were stained with Mito Tracker (red-CMX-ROS, Invitrogen), which causes actively respiring mitochondria to fluoresce red. The image in FIG. 1A (top panel) shows complete co-localization (yellow) of the mGFP autofluorescence (green) with the Mito Tracker (red). Similarly, expression of the V5-tagged mS9AGSK3 , using the V5 antibody for immunofluorescence staining, was also found to be completely co-localized with Mito Tracker (FIG. 1A , lower panel), verifying that both the expressed proteins are selectively localized to the mitochondria. The nuclei (Hoechst 33342, blue) are devoid of any staining of the expressed mitochondrial proteins. To examine the extent of mS9AGSK3 protein expression, a dose response and time course of doxycycline (Dox) treatment were performed, and whole cell lysates were immunoblotted for total GSK3 and for the V5 C-terminal tag on the expressed mS9AGSK3 . Robust expression of mS9AGSK3 commenced with as little as 0.05 g/ml Dox and reached maximum expression following the addition of 0.1 g/ml Dox (FIG. 1B) . Treatment of cells with 1 g/ml Dox increased the expression of mS9AGSK3 time-dependently, with mS9AGSK3 reaching maximum expression by 24 h and remaining at this level beyond 48 h following Dox treatment. The total increase in GSK3 protein levels (endogenous GSK3 plus mS9AGSK3 ) was 160% over control. There was essentially no expression of mS9AGSK3 in the absence of Dox indicating that the expression is tightly regulated. To further confirm that mS9AGSK3 was localized to the mitochondria and that there was no "leakage" of protein into the cytosol, cells treated without and with Dox were fractionated into cytosolic and mitochondrial fractions and immunoblotted with V5 antibody to detect mS9AGSK3 (FIG. 1C) . The expression of mS9AGSK3 was evident almost entirely in the mitochondrial fraction. An extended exposure of the immunoblot film did reveal a very minute amount of mS9AGSK3 in the cytosolic fraction, which could be newly synthesized protein destined for the mitochondria. To verify that FIGURE 1 Expression of mitochondrial-targeted constitutively active GSK3 . A. Cells were plated on glass cover slips, treated with 1 g/ml Dox for 24 h, and stained with MitoTracker (red-CMX-ROS). Top panels: cultured SH-SY5Y cells expressing mitochondrial-targeted GFP (mGFP), green GFP autofluorescence, and stained with Mito Tracker dye, red fluorescence. Bottom panels: V5-tagged mS9AGSK3 cells were immunofluorescently labeled with V5 antibody (green immunofluorescence) as described in "Methods", and stained with Mito Tracker dye. The green and red fluorescence images were merged (yellow) to reveal specific localization of mGFP and the V5-tagged mS9AGSK3 in mitochondria. Cells were stained with Hoechst 33342 to visualize the nucleus. The fluorescent staining was viewed and photographed using a fluorescence microscope. Size bar=10 m, 100x objective. B. Cells expressing mitochondrial-targeted constitutively active GSK3 (mS9AGSK3 ) were treated with 0.05, 0.1, 0.2, 0.5, 1, or 2 g/ml Dox for 24 h or 1 g/ml Dox for 10, 12, 16, 24, or 48 h, and whole cell lysates were immunoblotted for total GSK3 or the V5 tag. C. mS9AGSK3 cells were treated with 1 g/ml Dox, fractionated, and crude cytosolic and mitochondrial extracts were immunoblotted for V5 tag, -tubulin, and ATP synthase-. D. mS9AGSK3 cells were treated with 1 µg/ml Dox for 24 h and whole cell lysates were used to measure the activity of GSK3 as described in "Methods". Values are means ± S.E.M., n=3, *P <0.05, ANOVA.
mS9AGSK3 is constitutively active and to test the increase in GSK3 activity in Dox+ cells compared to the control Dox-cells, cells were induced with doxycycline for 24 h. Whole cell lysates were used to measure the overall increase in GSK3 activity as described in "Methods". The total GSK3 activity increased significantly by 162% (FIG. 1D) indicating that mS9AGSK3 is constitutively catalytically active.
Unregulated mitochondrial GSK3 activity facilitates apoptosis induced by mitochondrial complex I inhibition.
Previously, global expression of GSK3 was shown to enhance caspase-3 activity and apoptosis induced by mitochondrial complex I inhibitors (King et al., 2001) , endoplasmic reticulum stress , genotoxic stress (Watcharasit et al., 2002) , and staurosporine and heat shock (Bijur et al., 2000) . The goal was to test if unregulated GSK3 activity sequestered in the mitochondria would have similar affects on apoptosis signaling. Expression of mS9AGSK3 was induced by Dox treatment (1 g/ml) for 24 h. mS9AGSK3 expression alone did not cause any cell toxicity and no caspase-3 activity could be detected (FIG. 2A) . The control, non-induced (Dox-) cells, and the induced, mS9AGSK3 -expressing (Dox+) cells were treated with 5 mM MPP + , 5 M rotenone, 2 M thapsigargin, and 1 M camptothecin for 4 h. The caspase-3-dependent cleavage of the 116-kDa poly (ADP-ribose) polymerase (PARP) to the 85-kDa fragment during apoptosis (Tewari et al., 1995; Oliver et al., 1998) was measured by immunoblot analysis. Induction of mS9AGSK3 expression significantly augmented (FIG. 2A) MPP + -and rotenone-induced caspase-3 activities (FIG. 2A) , 264% and 395% of control. However, mS9AGSK3 expression did not potentiate caspase-3 activity induced by treatments with thapsigargin, an endoplasmic reticulum toxin, or camptothecin, a genotoxic agent. Caspase-3 activity was also induced by the complex II inhibitor 3-nitropropionic acid (3-NP) (Ludolph et al., 1992) (20 mM for 24 h), but mS9AGSK3 expression failed to cause any facilitation of 3-NP-induced apoptosis. Treatment of cells with staurosporine and heat shock also activated caspase-3, but mS9AGSK3 expression did not enhance caspase-3 activation by these general apoptosis inducers (data not shown). Expression of GFP in the mitochondria (mGFP) had no effects on MPP + and rotenone-induced caspase-3 activity (FIG. 2B) . To confirm that the facilitation of MPP + -and rotenone-induced apoptosis was due to increased GSK3 activity, cells were treated with two chemically different GSK3 inhibitors, 2-thio(3-iodobenzyl)-5-(pyridyl)-[1,3,4]-oxadiazole, also known as GSK3 inhibitor II (Naerum, et al., 2002) , and lithium (Klein and Melton, 1996) to determine if facilitation of caspase-3 activity could be blocked. Treatment of cells with GSK3 inhibitor II (5 M) 30 min prior to MPP + and rotenone treatments inhibited caspase-3 activity (FIG. 2C) and blocked the mS9AGSK3 -mediated enhancement of caspase-3 activity. Similarly, acute treatment of cells with lithium (20 mM) completely blocked the mS9AGSK3 -mediated facilitation of MPP + and rotenone-induced caspase-3 activity (FIG. 2D) . The blockade of caspase-3 activity by the GSK3 inhibitors indicates that increased GSK3 activity in the mitochondria enhances the toxicity of the complex I inhibitors. The augmentation of caspase-3 activity specifically by the complex I inhibitors, implies that GSK3 signaling converges on complex I.
Unregulated mitochondrial GSK3 inhibits complex I activity.
Given the fact that expression of mS9AGSK3 enhanced apoptosis induced by two different complex I inhibitors, but not other apoptosis inducers, we theorized that the deleterious effects of increased mitochondrial GSK3 may be mediated through a defect in complex I activity. Therefore, complex I activity was measured in mS9AGSK3 induced and non-induced cells. As hypothesized, complex I activity was found to be significantly attenuated by 70% in mS9AGSK3 -expressing cells compared to the noninduced cells (Table I) . Treatment of mS9AGSK3 -expressing cells with GSK3 inhibitor II reversed the repression of complex I activity. Lithium was also used to inhibit mS9AGSK3 activity; however, lithium was added directly to the mitochondrial lysates because lithium reversibly binds to the magnesium binding site of GSK3 , and the mitochondrial isolation process can easily disrupt the binding of lithium to GSK3 and reactivate the enzyme. The addition of lithium also significantly reversed GSK3 -mediated complex I inhibition (Table I) . Treatment with the GSK3 inhibitors alone in the non-induced control cells had no effects on complex I activity. Complex I activity was measured in the mGFP cells to further control for artifacts of increased protein expression. There was no significant difference in complex I activity in the mGFP induced cells compared to that of the non-induced cells (Table I) . Since the entry point of electrons from NADH is complex I, and a disruption of complex I should theoretically decrease energy production, mitochondrial ATP production was measured. ATP production by mitochondria from mS9AGSK3 -expressing cells decreased in parallel with the decreased complex I activity (FIG. 3) . GSK3 inhibitor II treatment of induced cells partially restored mitochondrial ATP production. Curiously, GSK3 inhibitor II treatment of non-induced cells caused a slight attenuation of ATP synthesis. Together this data shows that unregulated mitochondrial GSK3 severely impairs complex I activity and prevents normal mitochondrial ATP production.
Unregulated mitochondrial GSK3 activity induces reactive oxygen species (ROS) production. Complex I dysfunction has been shown to increase the generation of ROS (Hasegawa et al., 1990; Cleeter et al., 1992; Gonzalez-Polo et al., 2003) . To test if increased mitochondrial GSK3 activity also elevates intracellular ROS production, mS9AGSK3 expression was induced with Dox for 24 h and ROS production was measured. There was a significant increase in intracellular ROS production (137 ± 8%) in the mS9AGSK3 -expressing cells com-FIGURE 2 Unregulated mitochondrial GSK3 activity facilitates apoptosis induced by mitochondrial complex I inhibition, but not complex II inhibition, ER stress, nor genotoxic stress. A. mS9AGSK3 or mGFP cells were treated with Dox (1 g/ml) for 24 h in serum-containing media and were transferred to serum free media containing Dox for 1 h prior to treatment with 5 mM 1-methyl-4-phenylpyridinium (MPP + ), 5 M rotenone (ROT), 2 M thapsigargin (TG), 1 M camptothecin (CT), or 20 mM 3-nitropropionic acid (3-NP) for 4 h, and total cell lysates were immunoblotted for PARP. Quantitation of the proteolyzed PARP band for each sample is based on the percent of proteolyzed PARP from each sample's matched Dox-cells treated with the different apoptosis inducers. Values are means ± S.E.M., n=3, *P <0.05, ANOVA. B. Non-induced and induced mGFP cells were treated with 5 µM rotenone or 5 mM MPP + for 4 h, and total cell lysates were immunoblotted for PARP. mS9AGSK3 cells were treated with Dox (1 g/ml) for 24 h in serum-containing media and were transferred to serum free media containing Dox for 1 h and (C) 5 pared to the non-induced cells (FIG. 4A) , and postinduction treatment with GSK3 inhibitor II completely blocked mS9AGSK3 -mediated ROS production (FIG. 4A) . Furthermore, treatment with lithium also significantly reduced the levels of intracellular ROS in mS9AGSK3 -expressing cells (FIG. 4B) . Treatment of the non-induced control cells with the GSK3 inhibitors did not markedly affect ROS levels. As another control, SH-SY5Y cells that constitutively express the tetracycline repressor were also treated with doxycycline. There was no significant increase in ROS production following Dox treatment of control cells, indicating that Dox treatment alone did not affect intracellular ROS production (FIG. 4C) .
Increased mitochondrial GSK3 activity alters mitochondrial morphology. Aberrant mitochondrial function, including complex I deficiency and elevations in intracellular ROS production can affect mitochondrial morphology (Koopman et al., 2008) and cause mitochondrial fission. Therefore, to test if increased expression of mS9AGSK3 alters mitochondrial morphology, mS9AGSK3 cells were treated with Dox, stained with Mito Tracker, and immunofluorescently labeled with GSK3 antibody. The diffuse green staining is endogenous GSK3 , but the expressed mS9AGSK3 which appears punctate Table I Complex I activity. Isolated mitochondria were used to measure complex I activity as described in "Methods". The mS9AGSK3 or the mGFP cells were treated with Dox (1 g/ml) for 24 h in serum-containing media and were transferred to serum free media containing Dox for 5 h or (mS9AGSK3ß) 30 min prior to treatment with 5 M GSK3 inhibitor II for 4.5 h. The mitochondrial lysates from the non-induced and the induced mS9AGSK3 cells were incubated with 20 mM lithium for 30 min prior to measuring complex I activity. Values are represented as means ± S.E.M., n=3, *P <0.05, compared to the non-induced mS9AGSK3 cells.
FIGURE 3 Unregulated mitochondrial GSK3 activity decreases mitochondrial ATP production. mS9AGSK3 cells were treated with Dox (1 g/ml) for 24 h in serum media, and crude mitochondria were isolated from noninduced and induced cell cultures treated with and without 5 M GSK3 inhibitor II for 4.5 h. ATP generation was measured as described in "Methods".
colocalizes with the Mito Tracker (FIG. 5A) . Interestingly, the mitochondria themselves appear fragmented in the mS9AGSK3 -expressing cells. Upon closer observation the mitochondria in the control mGFP-expressing cells and the non-induced mS9AGSK3 cells appear fibrous (FIG. 5B) . By contrast, in cells expressing mS9AGSK3 , the mitochondria appear fragmented and punctiform (FIG. 5B) . Post-induction treatment of the mS9AGSK3 cells with GSK3 inhibitor II partially restored the mitochondrial morphology (FIG. 5B) although some fragmented mitochondria were still evident.
To more closely visualize mitochondrial morphology, the mitochondria were viewed by transmission electron microscopy. Normal mitochondria in control cells displayed classical morphological features, including an elongated shape with well-defined cristae, as seen in the mGFPexpressing cells and the mS9AGSK3 noninduced cells (FIG. 5C) . However, the morphology of the mitochondria appeared smaller in size in cells expressing mS9AGSK3 . Moreover, the cristae appeared more de-convoluted and vacuole-like in the mS9AGSK3 -expressing cells compared to the non-induced cells (FIG. 5D) . To test if inhibition of mS9AGSK3 rectifies the aberrant mitochondrial morphology, mS9AGSK3 expression was induced for 24 h followed by post-induction treatment with GSK3 inhibitor II or lithium. Treatment of cells with GSK3 inhibitor II or lithium (data not shown) reversed the affects of mS9AGSK3 expression on mitochondrial morphology (FIG.  5C) , as they resembled mitochondria in the control cells. Area quantitation revealed that the size of mitochondria in the mS9AGSK3 -expressing cells was significantly (50%) smaller than the mitochondria in the mS9AGSK3 non-induced cells (FIG. 5E) . Treatment of the mS9AGSK3 -expressing cells with GSK3 inhibitor II or with lithium either partially or completely, respectively restored the mitochondria to their original size (FIG. 5E ). There were no significant differences in mitochondrial size in the mGFP-expressing cells and the mS9AGSK3 non-induced cells (FIG. 5E) . Thus, unregulated GSK3 activity can affect gross mitochondrial morphology.
FIGURE 4 Unregulated mitochondrial GSK3 activity increases intracellular ROS production. mS9AGSK3 cells were treated with Dox for 24 h in serum media and were transferred to Dox-treated serum free media for 30 min prior to treatment with (A, top) 5 M GSK3 inhibitor II (Inhib II) or (B, middle) 20 mM lithium for 4.5 h, and intracellular ROS production was measured as described in "Methods". C, bottom. SH-SY5Y/Tet-R control cells were treated with Dox (1 g/ml) for 24 h in serum media and were transferred to Dox-treated serumfree media for 5 h, and intracellular ROS production was measured. Values are means ± S.E.M., n=3, *P <0.05, ANOVA. FIGURE 5 (C-D) mGFP and mS9AGSK3 cells were treated and prepared for transmission electron microscopy as described in the "Methods". The size bar in C = 500 nm and the size bar in D = 100 nm. E. Mitochondrial area was measured in pixels. "In II" is inhibitor II. Values are means ± S.E.M., 48 to 62 mitochondria per grid for each sample were counted, *P <0.05, ANOVA.
DISCUSSION
GSK3 is typically viewed as one continuous intracellular pool, but in reality endogenous GSK3 exists within different subcellular compartments, including the mitochondria (Bijur and Jope, 2003a; Hoshi et al., 2003) , and it has previously been shown that this fraction of GSK3 is highly activated relative to GSK3 in the cytosol (Bijur and Jope, 2003b) . However, almost nothing is known about how GSK3 signaling emanating from within the mitochondria affects this organelle. The key finding in this study is that expression of constitutively active GSK3 inside the mitochondria robustly inhibits complex I function.
It is now well established that unregulated GSK3 augments apoptosis signaling. Our initial goal was to determine if increased GSK3 activity within the confines of the mitochondria would have similar affects on apoptosis. However, expression of mS9AGSK3 alone did not activate caspase-3, but it did facilitate apoptosis induced by two apoptosis inducers known to be influenced by GSK3 overexpression, MPP + and rotenone. A variety of apoptosis inducers were tested; including thapsigargin, an endoplasmic reticulum toxin, and camptothecin, a genotoxic agent, as well as the general apoptosis inducers heat shock and staurosporine (data not shown), none of which were affected by mS9AGSK3 expression. However, caspase-3 activation by two chemically unrelated complex I inhibitors, MPP + and rotenone, was significantly enhanced by mS9AGSK3 expression. Interestingly, untargeted overexpression of GSK3 has been shown to enhance apoptosis by all of these treatments (Bijur et al., 2000; King et al., 2001; Watcharasit et al., 2002) , but overexpression of GSK3 in the mitochondria selectively potentiated caspase-3 activity induced by the complex I inhibitors. To test if mS9AGSK3 was simply enhancing the toxicity of mitochondrial toxins, cells were treated with the complex II inhibitor 3-NP. However, 3-NP-induced caspase-3 activity was also unaffected by mS9AGSK3 expression, which indicates that unregulated mitochondrial GSK3 activity selectively exacerbates the effects of complex I inhibition. On the basis of this result it was theorized that GSK3 might be affecting complex I function and bolstering the toxicity of the complex I inhibitors.
Complex I, (NADH:ubiquinone oxidoreductase, EC 1.6.5.3), is the point of entry for electrons destined for the electron transport chain from NADH. It is also the least understood and the largest protein component of the electron transport chain. Measurement of complex I activity from isolated mitochondria revealed that expression of the mS9AGSK3 significantly reduces complex I function and this decrease in activity could be reversed by the GSK3 inhibitors GSK3 inhibitor II and lithium. However, GSK3 inhibitor treatments alone did not increase basal complex I activity, indicating that normal endogenous GSK3 activity does not suppress complex I. Recently, it was shown that MPP + and rotenone treatments increase overall GSK3 activity (Wang et al., 2007; . In addition, a previous report by our group (King et al., 2001) showed that inhibition of the upstream phosphatidylinositol 3-kinase/Akt signaling pathway, which is known to activate GSK3 , and untargeted overexpression of GSK3 facilitated MPP + and rotenone-induced apoptosis. However, none of these studies identified the different intracellular pools of GSK3 that are activated. Nevertheless, it is conceivable that increased GSK3 activity could contribute to the inhibition of complex I by MPP + and rotenone and partially contribute to their apoptosis-inducing effects. Normal complex I function maintains the proton gradient across the inner mitochondrial membrane which is required for ATP production. ATP synthesis was noticeably decreased by isolated mitochondria from mS9AGSK3 -expressing cells compared to control cells, which could be partially reversed by GSK3 inhibitor II treatment. Since complex I is the first point of entry for electrons it therefore makes sense that disabling complex I function by unregulated mitochondrial GSK3 activity would markedly affect mitochondrial energy production. Thus, this is the first report showing unregulated GSK3 as a potent complex I inhibitor; however, the exact mechanisms by which GSK3 inhibits complex I remain to be elucidated.
Complex I is known to be one of two major sources of ROS in the electron transport chain, the other being complex III (Camello-Almarez et al., 2006; Grivennikova and Vinogradov, 2006) . Complex I inhibitors including MPP + and rotenone have previously been shown to increase ROS production (Hasegawa et al., 1990; Cleeter et al., 1992; Gonzalez-Polo et al., 2003) . Since increased mitochondrial GSK3 activity impairs complex I function we hypothesized that unregulated mitochondrial GSK3 activity would also enhance ROS production. In fact, increased expression of mS9AGSK3 facilitated the production of ROS and inhibition of mitochondrial GSK3 with GSK3 inhibitor II and lithium completely blocked GSK3 -mediated ROS production.
The most visible sign that unregulated GSK3 affects mitochondria was the morphological changes of Mito Tracker-stained mitochondria and the observable decrease in the size of mitochondria in mS9AGSK3 -expressing cells. Since increased mitochondrial GSK3 activity bolstered ROS production, it is likely that ROS triggers mitochondrial fission. In a recent study, ROS levels were discovered to be higher in cells with fragmented mitochondria (Koopman et al., 2008) . Also, in that same study, Hela cells were transfected with dynaminrelated protein-1, an important mediator in mitochondrial fission, which induced mitochondrial fragmentation but not ROS production; thus, suggesting that ROS may act upstream of mitochondrial fission. Although it is not known how ROS may facilitate mitochondrial fission, it is thought that increases in intracellular ROS levels may regulate the expression and/or recruitment of mitochondrial fission/fusion proteins (Koopman et al., 2008) . Therefore, the abundance of fragmented mitochondria in the mS9AGSK3 -induced cells but not in the mS9AGSK3 -non-induced cells or the mGFPinduced cells may be a result of increased GSK3 -mediated ROS production. The facilitation of MPP + -or rotenone-induced apoptosis by mS9AGSK3 may be due in part to an increase in mitochondrial fission caused by GSK3 -mediated inhibition of complex I. Mitochondrial fission under normal conditions does not necessarily elicit the activation of downstream effector caspases (reviewed in Bossy-Wetzel et al., 2003) ; however, increased mitochondrial fission may sensitize the cells to certain apoptosis inducers including MPP + and rotenone. Therefore, an increase in mitochondrial GSK3 activity may serve to prime mitochondria for the release of pro-apoptotic factors (i.e., AIF, cytochrome c) from the mitochondria upon stimulation with complex I inhibitors.
The findings in this report are particularly interesting from the standpoint that complex I dysfunction has been intrinsically linked most notably to Parkinson's disease (Parker et al., 1989; Swerdlow et al., 1996; Gu et al., 1998) . Abnormal mitochondrial morphology, which may be indicative of excessive mitochondrial fission, has also been linked to neurodegenerative diseases, including Parkinson's disease (Trimmer et al., 2000) . MPP + and rotenone are well known Parkinson's disease-mimetic toxins that cause selective apoptosis of dopaminergic neurons (Javitch et al., 1985; Betarbet et al., 2000) and motor deficits in animal models mirroring the palsy seen in this neurodegenerative disease. There is also growing evidence of GSK3 's involvement in Parkinson's disease (King et al., 2001; Chen et al., 2004; Avraham et al., 2005; Chung et al., 2007; Wang et al., 2007; Yuan et al., 2008) . The present report illustrates that unregulated GSK3 in the mitochondria inhibits complex I activity, one of the major hallmarks of Parkinson's disease pathophysiology, the sequelae of which includes oxidative stress, decreased ATP production, and mitochondrial fission. Taken together, these studies raise the possibility that mitochondrial GSK3 could be a potential target for Parkinson's disease treatment.
